The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from CNW Group

Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting

Monday, November 26, 2012

Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting07:30 EST Monday, November 26, 2012QUÉBEC CITY, Nov. 26, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that final Phase 2 data for perifosine, its oral AKT inhibitor, combined with sorafenib in patients with relapsed/refractory lymphomas, will be presented at the upcoming American Society of Hematology ("ASH") annual meeting in Atlanta, Georgia, December 8-11, 2012. Data will be disclosed during a poster presentation by Anna Guidetti, MD, of the Fondazione IRCCS Instituto Nazionale Tumori, Milan, Italy.Abstract #3679: "Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase 2 Trial", A Guidetti, S. Viviani, A. Marchiano, A. Dodero, L. Farina, S.L. Locatelli, D. Russo, P. Bulian, R. Sorasio, M. Di Nicola, L. Giordano, P. Corradini, A.M. Gianni, C. Carlo-Stella.  Poster Session #624: "Lymphoma-Therapy with Biologic Agents, Excluding Pre-Clinical Models: Poster III"Date & Time: Monday, December 10, 2012, from 6 pm to 8 pm (Eastern) Venue:  Georgia World Congress Center, Hall B1-B2, Level 1, Building BAbout PerifosinePerifosine is a novel, oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. It has been granted orphan drug and orphan medicinal product designations for multiple myeloma ("MM") from the FDA and the European Medicines Agency ("EMA"), respectively. Perifosine has also received Fast Track designation from the FDA. The ongoing Phase 3 trial in MM is conducted under a Special Protocol Assessment from the FDA and a positive Scientific Advice from the EMA, with positive results from this trial expected to be sufficient for registration in the US and Europe. Perifosine is also being explored in combination therapy and in monotherapy in other cancer indications. Aeterna Zentaris holds worldwide rights to perifosine except for Japan, Korea and MENA (Middle East and North Africa) region, where licensing rights have been granted to Yakult Honsha, Handok and Hikma Pharmaceuticals respectively.About Aeterna Zentaris Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit www.aezsinc.com.  SOURCE: AETERNA ZENTARIS INC.For further information: Investor Relations Ginette Beaudet Vallières Investor Relations Coordinator (418) 652-8525 ext. 265 gvallieres@aezsinc.com Media Relations Paul Burroughs Director of Communications (418) 652-8525 ext. 406 pburroughs@aezsinc.com